对切除性结直肠癌的术后预后进行比较,使用倾向得分匹配分析与没有瘤紧急情况进行比较:单中心回顾性观察性研究

Ken Imaizumi1, Hiroyuki Kasajima1, Kentaro Sato1

  • 1Department of Gastroenterological Surgery, Hakodate Municipal Hospital, Hakodate, Hokkaido 041-8680, Japan.

Oncology letters
|October 14, 2024
PubMed
概括

与非紧急病例相比,结肠直肠癌瘤紧急情况会使患者的预后恶化. 辅助化疗显著改善了急诊患者的无复发生存率,这需要深入考虑.

相关概念视频

Cancer Survival Analysis01:21

Cancer Survival Analysis

Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
328
Comparing the Survival Analysis of Two or More Groups01:20

Comparing the Survival Analysis of Two or More Groups

Survival analysis is a cornerstone of medical research, used to evaluate the time until an event of interest occurs, such as death, disease recurrence, or recovery. Unlike standard statistical methods, survival analysis is particularly adept at handling censored data—instances where the event has not occurred for some participants by the end of the study or remains unobserved. To address these unique challenges, specialized techniques like the Kaplan-Meier estimator, log-rank test, and...
156
Kaplan-Meier Approach01:24

Kaplan-Meier Approach

The Kaplan-Meier estimator is a non-parametric method used to estimate the survival function from time-to-event data. In medical research, it is frequently employed to measure the proportion of patients surviving for a certain period after treatment. This estimator is fundamental in analyzing time-to-event data, making it indispensable in clinical trials, epidemiological studies, and reliability engineering. By estimating survival probabilities, researchers can evaluate treatment effectiveness,...
103